CClinicalTrials.gg
Status unknownNCT02881905Updated Sep 12, 2016

PeriImplant Soft Tissue and Marginal Bone Loss of Single Implant Mandibular Overdenture

An interventional study of ball attachment and cm loc attachment in Complete Edentulism, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to participants aged 50 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-12.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
50 Years to 69 Years
Sex
All
01

Study summary

There is a significant difference between CM LOC and ball attachment, when considering the peri-implant soft tissue health and marginal bone loss. The primary and secondary objectives are to determine if CM LOC attachment improves the peri-implant soft tissue response and decreases the marginal bone loss around implant when compared to conventional ball attachment

Read the detailed description

Ball attachments are very commonly used because they are solitary, simple, easier to use and less technique sensitive if compared to bar attachments. However, ball attachment require a prosthetic space of 12 mm and could show tremendous wear if implants were mal-aligned. CM LOC attachment is newly introduced into market with very good expectations regarding its properties and effect on the periimplant soft tissue. CM LOC attachment, which combes titanium patrix and resin matrix made from polyetherketoneketone (PEKK), is a very promising material regarding the wear and the prosthesis retention it provides, even with mal-aligned implants. However, the clinical performance of this attachment was not tested yet. Therefore, in this randomized controlled trial it was decided to compare between CM LOC and the commonly used ball attachment regarding the soft tissue health and marginal bone loss.

02

Conditions studied

  • Complete Edentulism
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Completely edentulous male or female patients between the ages of 50 to 69.
  • No contraindications for implantation.
  • Each patient has to perform both a random blood sugar and Glycosylated Hemoglobin analysis. Patients with a Glycosylated hemoglobin test HbA1c up to 8% and a normal blood sugar level (79 to 110) or controlled diabetic patients (90-130 fasting according to American Association of Diabetes) will be included.
  • Sufficient bone width (≥ 6 mm) in the anterior region to place an implant. It could be either normally present or achieved by bone plateauing. This will be confirmed by cone beam computed tomographic (CBCT) scans.
  • Residual bone height ranging from 11-20 mm with the lowest vertical height in the midline of the mandible not less than 13 mm (Class II or III according to McGarry et al[16] 1999). This will be confirmed by the CBCT.
  • Patients seeking to install a single symphyseal implant and for whom new dentures will be constructed.
  • Patients, who are dissatisfied with the retention and stability of their technically satisfactory dentures.
  • Patients, who already have existing maxillary and mandibular complete dentures, and after examination of the mandibular dentures, it is found that there are technical problems with regard to denture design and/or occlusion; then new maxillary and mandibular dentures will be fabricated
  • All patients should have adapted to their dentures for at least six weeks before being included in the trial.
  • Patients providing written informed consents to participate in the trial and this will be done before the scheduled date for implant installation.

Exclusion criteria

Exclusion Criteria:

  • Patients with a systemic or local contra-indication for implant placement.
  • Satisfied patients with the retention of their mandibular denture as well as unsatisfied patients with their maxillary denture.
  • Patient with a mandibular denture height less than 6 mm between the base of the denture and the incisal edge of the central incisors (as measured by a caliper) or with 12 mm crown height space as measured by a ruler from the incisal edge till the crest of the ridge. This will be done from a putty index of the diagnostic set up.
  • Incompliant and not cooperative patients.
  • Patients smoking more than 10 cigarettes per day.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Active comparator
    ball attachment

    completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment

    Device: ball attachment

  • Experimental
    CM LOC attachment

    completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment

    Device: cm loc attachment

Interventions

  • Deviceball attachment

    it is attachment part that connects the overdenture to the implant

    Also known as: metallic ball attachment

  • Devicecm loc attachment

    It is a new attachment made of peek material

06

What researchers measure

Primary outcomes

  1. Soft tissue reaction :Presence of mucositis

    it is a binary outcome that is measured by either its presence or absence

    Time frame: [from baseline up to 1 year]

Secondary outcomes

  1. Modified gingival Index

    0 = absence of inflammation 1. = mild inflammation or with slight changes in color and texture but not in all portions of gingival marginal or papillary 2. = mild inflammation, such as the preceding criteria, in all portions of gingival marginal or papillary 3. = moderate, bright surface inflammation, erythema, edema and/or hypertrophy of gingival marginal or papillary 4. = severe inflammation: erythema, edema and/or marginal gingival hypertrophy of the unit or spontaneous bleeding, papillary, congestion or ulceration. Gingival units as well as the calculation of the index follow the same criteria described in GI

    Time frame: from baseline up to 1 year. score measurement from 0-4 where 0 is no inflammation and 4 is severe inflammation

  2. Modified Plaque Index

    Modified Plaque Index (mPI) is a dental plaque scale done by Mombelli etal.\[13\] as follows: 0 = No plaque 1. = Separate flecks of plaque at the cervical margin 2. = Plaque can be seen by naked eye 3. = Abundance of soft matter. The lower the number the less plaque is present on the tooth

    Time frame: from baseline upto 1 year. score measurement from 0-3 where 0 denotes no plaque present and 3 denotes abundant plaque

  3. Modified Bleeding Index

    Periodontal probe will be passed all around implant cervical margin and bleeding will be scored as follows: Score 0: No bleeding when a periodontal probe is passed along the gingival margin adjacent to the implant. Score 1: Isolated bleeding spots visible. Score 2: Blood forms a confluent red line on margin. Score 3: Heavy or profuse bleeding.

    Time frame: from baseline upto 1 year. score from 0-3 where 0 denotes no bleeding and 3 denotes profound bleeding

  4. marginal bone loss

    Standardized periapical long cone paralleling technique will be necessary so radiographic template customized for each patient with a holder. Then two reference points will be marked on the implant platform surface and will be joined with a line representing the height zero. then two vertical lines mesial and distal will be drawn to the first bone contact point.

    Time frame: from baseline up to 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02881905
Lead sponsor
Cairo University
Collaborators
University of Kiel
Responsible party
Ahmed Salah Hamed Sherif (associate lecturer, Cairo University) — Principal investigator
First posted
Aug 29, 2016
Start date
Jul 2016
Primary completion
Jul 2017 (estimated)
Completion
Jul 2021 (estimated)
Last update
Sep 12, 2016

Study contacts

ahmed sherif, Msc
Contact
ahmed.sherif@dentistry.cu.edu.eg
00201002130130
Hassan ahmed
Contact
Hassan.ahmed@dentistry.cu.edu.eg
0020105009014
nouran abdelnaby, phd
study director · prosthodontic department-faculty of dentistry-cairo university

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion